Published by Iain Gilbert on 10th October 2025
(Sharecast News) - Clinical-stage biotechnology firm Sareum said on Friday that it has discontinued its 16-week pre-clinical toxicology study for autoimmune and cancer candidate SDC-1801 after safety issues were flagged by a third-party provider.
URL: http://www.digitallook.com/dl/news/story/35414327/...